布地奈德霧化吸入與干擾素聯合治療病毒性肺炎臨床分析

黃靜　邸金紅　王秀娟

【摘要】 目的：觀察布地奈德霧化吸入與干擾素聯合治療病毒性肺炎的臨床效果。方法：選取筆者所在醫院2017年1月-2019年12月兒科住院的病毒性肺炎患兒162例，采用隨機數字表法將其隨機分為兩組，每組81例。對照組應用利巴韋林霧化吸入治療，觀察組應用布地奈德霧化吸入與干擾素聯合治療。比較兩組臨床效果。結果：觀察組治療總有效率為88.89%，高于對照組的67.90%，差異有統計學意義（P<0.05）。兩組治療7 d

后臨床癥狀及體征評分均低于治療前，且觀察組低于對照組，差異有統計學意義（P<0.05）。觀察組治療7 d后CD3+、CD4+、CD4+/CD8+均高于對照組，CD8+低于對照組，差異均有統計學意義（P<0.05）。結論：布地奈德霧化吸入與干擾素聯合治療病毒性肺炎臨床效果顯著，是有效的聯合用藥方案。

【關鍵詞】 布地奈德 霧化吸入 干擾素 病毒性肺炎 臨床效果

doi：10.14033/j.cnki.cfmr.2020.16.057 文獻標識碼 B 文章編號 1674-6805（2020）16-0-03

Clinical Analysis of Budesonide Atomization Inhalation Combined with Interferon in the Treatment of Viral Pneumonia/HUANG Jing， DI Jinhong， WANG Xiujuan. //Chinese and Foreign Medical Research， 2020， 18（16）： -142

[Abstract] Objective： To observe the clinical effect of Budesonide atomization inhalation combined with Interferon in the treatment of viral pneumonia. Method： A total of 162 pediatric patients with viral pneumonia hospitalized in our hospital from January 2017 to December 2019 were selected and randomly divided into two groups according to the random number table method， with 81 cases in each group. The control group was treated with Ribavirin atomization inhalation， and the observation group was treated with Budesonide atomization inhalation combined with Interferon. The clinical effects of the two groups were compared. Result： The total effective rates of the observation group was 88.89%， which was higher than 67.90% of the control group， and the difference was statistically significant （P<0.05）. The scores of clinical symptoms and signs in the two groups were lower than those before treatment after 7 d treatment， the score of clinical symptoms and signs in the observation group were lower than those in the control group after 7 d treatment， the differences were statistically significant （P<0.05）. The CD3+， CD4+ and CD4+/CD8+ in the observation group were all higher than those in the control group， and CD8+ was lower than that in the control group， and the differences were statistically significant （P<0.05）. Conclusion： Budesonide atomization inhalation combined with Interferon has a remarkable clinical effect in the treatment of viral pneumonia， and is an effective combined drug regimen.

[Key words] Budesonide Atomization inhalation Interferon Viral pneumonia Clinical effect

First-authors address： Baoding Fourth Central Hospital， Tangxian 072350， China

病毒性肺炎是指由多種病原體經呼吸道等途徑侵入肺部，引起肺部感染，發生局部炎癥的疾病。由于小兒免疫能力低下，因此該病在小兒中十分常見，需要適宜的治療。利巴韋林霧化吸入是一種常見的治療方法，利巴韋林霧化吸入雖然有顯著的抗病毒作用，但緩解患兒癥狀仍然較慢，因此需要更有效的治療方案[1]。本研究選取筆者所在醫院自2017年1月-2019年12月兒科住院的病毒性肺炎患兒162例，對布地奈德霧化吸入與干擾素聯合治療病毒性肺炎臨床效果進行研究，現報道如下。

綜上所述，采用布地奈德霧化吸入與干擾素聯合治療病毒性肺炎可改善患兒臨床癥狀，治療效果顯著，是一種值得推廣應用的聯合治療方案。

參考文獻

[1] Razi C H，Akelma A Z，Harmanci K，et al.The Addition of Inhaled Budesonide to Standard Therapy Shortens the Length of Stay in Hospital for Asthmatic Preschool Children：A Randomized，Double-Blind， Placebo-Controlled Trial[J].International Archives of Allergy and Immunology，2015，166（4）：297-303.

[2]侍蘇杰.重組人干擾素α-1b聯合布地奈德霧化治療小兒支氣管肺……